Holen Sie sich die Stockscreener-App
5.80
2.68%
-0.16
Schlusskurs vom Vortag:
$5.96
Offen:
$6.01
24-Stunden-Volumen:
1.73M
Relative Volume:
1.35
Marktkapitalisierung:
$348.79M
Einnahmen:
$217.78M
Nettoeinkommen (Verlust:
$-239.55M
KGV:
-1.4324
EPS:
-4.0492
Netto-Cashflow:
$-127.30M
1W Leistung:
-4.92%
1M Leistung:
-4.61%
6M Leistung:
-13.04%
1J Leistung:
+28.04%
1-Tages-Spanne:
$5.745
$6.12
1-Wochen-Bereich:
$5.61
$6.145
52-Wochen-Spanne:
$4.14
$9.94
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Firmenname
Vanda Pharmaceuticals Inc
Sektor
Branche
Telefon
202-734-3400
Adresse
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
5.80 | 348.79M | 217.78M | -239.55M | -127.30M | -4.0492 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-05 | Eingeleitet | Truist | Buy |
| 2025-11-05 | Eingeleitet | B. Riley Securities | Buy |
| 2024-10-31 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-02-25 | Herabstufung | Jefferies | Buy → Hold |
| 2021-05-12 | Eingeleitet | BofA Securities | Buy |
| 2021-01-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-03-16 | Herabstufung | Oppenheimer | Perform → Underperform |
| 2020-03-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-11-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-08-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-07-25 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2018-12-04 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | Bestätigt | Jefferies | Buy |
| 2018-11-08 | Fortgesetzt | Jefferies | Buy |
| 2018-09-21 | Fortgesetzt | Oppenheimer | Outperform |
| 2018-05-23 | Eingeleitet | Citigroup | Buy |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
| 2017-09-14 | Bestätigt | Piper Jaffray | Overweight |
| 2017-06-27 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-05-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-04-12 | Eingeleitet | Oppenheimer | Outperform |
| 2016-11-09 | Eingeleitet | Aegis Capital | Buy |
| 2016-10-06 | Fortgesetzt | Jefferies | Buy |
Alle ansehen
Vanda Pharmaceuticals Inc Aktie (VNDA) Neueste Nachrichten
Watch VANDA Pharmaceuticals Berlin Tennis Open (Quarterfinals) | Disney+ - Disney Plus
Vanda Pharmaceuticals Inc (VNDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Why Did Vanda Pharmaceuticals Stock Slide 7% Pre-Market Today? - Stocktwits
Watch VANDA Pharmaceuticals Berlin Tennis Open / Court 1 (Doubles Quarterfinals) | Disney+ - Disney Plus
Vanda Pharmaceuticals Inc (VNDA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vanda Pharmaceuticals Inc (VNDA) Institutional Confidence - TradingKey
Vanda Pharmaceuticals Inc (VNDA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vanda Pharmaceuticals Inc (VNDA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vanda Pharmaceuticals Inc (VNDA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Vanda Pharmaceuticals Inc (VNDA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Vanda Pharmaceuticals Inc (VNDA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vanda Stock Draws Heavy Buzz Ahead Of FDA Verdict On Bysanti For Bipolar, Schizophrenia - Stocktwits
VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? - Stocktwits
Watch VANDA Pharmaceuticals Berlin Tennis Open / Court 1 | Disney+ - Disney Plus
Vanda Pharmaceuticals Faces New Market Challenges Amid Share Sale and Regulatory Roadblocks - timothysykes.com
Watch VANDA Pharmaceuticals Berlin Tennis Open / Steffi Graf Stadion | Disney+ - Disney Plus
Vanda Pharmaceuticals Stock Price Forecast. Should You Buy VNDA? - StockInvest.us
VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug - Stocktwits
VNDA Stock Rallies After-Hours As FDA Approves Schizophrenia, Bipolar Disorder Drug - Stocktwits
80,000-share RSU grant to Vanda (VNDA) SVP and General Counsel - Stock Titan
Vanda Pharmaceuticals (VNDA) director granted 41,600 RSU shares vesting in 2027 - Stock Titan
Vanda (NASDAQ: VNDA) director awarded 41,600 RSU-based shares - Stock Titan
Vanda Pharmaceuticals (VNDA) director receives 41,600-share RSU award - Stock Titan
Vanda Pharmaceuticals (VNDA) director receives 41,600-share RSU grant - Stock Titan
Vanda Pharmaceuticals (VNDA) grants director 41,600 RSUs vesting in 2027 - Stock Titan
Vanda Pharmaceuticals (VNDA) SVP McGuire reports RSU awards vesting through 2029 - Stock Titan
Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder - Stocktwits
Vanda Pharmaceuticals 2026 Annual Meeting Results: Director Elections, Auditor Ratification, and Plan Amendment Approved - minichart.com.sg
Vanda (NASDAQ: VNDA) investors approve directors, auditor and equity plan shares - Stock Titan
Earnings call transcript: Vanda Pharmaceuticals misses Q1 2026 forecasts, stock rises - Investing.com
Gastroparesis Market Shows Strong Future Potential with Increasing Industry Investments by 2036 – DelveInsight | Vanda Pharma, Dr. Falk Pharma GmbH, Alfasigma S.p.A., PTC Therapeutics, CinDome Pharma - Barchart.com
Gastroparesis Market Shows Strong Future Potential with - openPR.com
Vanda Pharmaceuticals stock rating reiterated at Buy by H.C. Wainwright - Investing.com
Why did Vanda Pharmaceuticals stock slide 7% pre-market today? - MSN
Earnings call transcript: Vanda Pharmaceuticals Q1 2026 misses EPS forecast, stock drops - Investing.com Nigeria
Vanda Pharmaceuticals (VNDA) Shares Rise 3.75% as Stock Tests Key ResistanceWMA Signal - The Legal Advocate
H.C. Wainwright Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan - GuruFocus
Vanda gets orphan drug status in Japan for imsidolimab By Investing.com - Investing.com Australia
Vanda Pharmaceuticals (VNDA) Secures Orphan Drug Status in Japan - GuruFocus
Vanda gets orphan drug status in Japan for imsidolimab - Investing.com
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis - Barchart
Japan gives special status to Vanda drug for rare, severe skin disease - Stock Titan
Vanda a new buy at B. Riley on 'historic discount' - MSN
Vanda Pharmaceuticals Inc (VNDA) Stock Price, Quote, News & History - Benzinga
Finanzdaten der Vanda Pharmaceuticals Inc-Aktie (VNDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):